Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
Ability to serially monitor treatment response, identify key biomarkers and customize assay aids clinical research efforts to improve treatment for metastatic cancers involving brain and spinal cord SAN DIEGO --(BUSINESS WIRE)--Feb. 22, 2022-- Biocept, Inc .
View HTML
Toggle Summary Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W.
View HTML
Toggle Summary Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
SAN DIEGO --(BUSINESS WIRE)--Feb. 10, 2022-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer. With more than 30 years of healthcare experience,
View HTML
Toggle Summary Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
SAN DIEGO --(BUSINESS WIRE)--Jan. 21, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.
View HTML
Toggle Summary Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
SAN DIEGO --(BUSINESS WIRE)--Jan. 4, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held
View HTML
Toggle Summary Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
Spotlight Presentation at SABCS showed that in 38% of patients the HER2 status of the metastatic cancer differed from the primary tumor, offering new information to aid treatment decisions SAN DIEGO --(BUSINESS WIRE)--Dec. 9, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular
View HTML
Toggle Summary Quest Diagnostics Now Offers Biocept’s Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer Diagnostics
Targeted Lung Panel Now Available with Physician’s Order at Quest’s 2,200 Patient Service Centers Nationwide SECAUCUS, N.J. AND SAN DIEGO – December 1, 2021 – Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics
View HTML
Toggle Summary Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
Biocept continues to expand and perform COVID-19 testing services using Thermo Fisher Scientific platform SAN DIEGO --(BUSINESS WIRE)--Nov. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, now offers a single test that can detect
View HTML
Toggle Summary Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced the presentation of a multi-institutional case
View HTML
Toggle Summary CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Third paragraph, sixth sentence of release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six of eleven using cytology.
View HTML